The retail sales volume of nasal decongestant medications in Russia from January to September 2025 reached 28.9 billion rubles and 230.9 million packages, a 9.7% and 3.2% increase y-o-y, respectively. According to RNC Pharma analysts, this is the lowest monetary figure and the highest physical volume over the past three years.
This year saw a new leader emerge in the nasal decongestant category, with the brand Otrivin (Haleon) claiming the number one position. Otrivin’s sales rose 28% in monetary terms, securing a 15% market share. Meanwhile, the previous long-standing leader, Snoop (Nizhpharm Group), saw its sales fall 9% year-on-year, causing it to drop to second place with a 13% share. Securing third place was Teva’s Rhinonorm, which was the fastest-growing brand among the top products, with sales up 32% over the year.
In March, Amgen and AstraZeneca reported complete outcomes from the registrational Phase 3 trial of Tezspire (tezepelumab-ekko) for treating chronic rhinosinusitis with nasal polyps. Read more about the new treatment method in the GxP News article.